Skip to main content

$0.860 0.010 (1.18%)

High

$0.88

Low

$0.86

Trades

19

Turnover

$55,369

Volume

64,140
30 June 2023 at 3:08pm
Register to track PIQ and receive email alerts.
Subject
PIQ Ann: September 2022 Quarterly Activities Report and Appendix 4C

PIQ Ann: Change of Directors' Interest Notices x2

PIQ Ann: Exercise of Director Options

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Precision diagnostics facility receives $2m funding boost

PIQ Ann: Notice of Annual General Meeting/Proxy Form

PIQ Ann: Proteomics receives $1.7 million in R&D tax incentive

PIQ Ann: Notification of cessation of securities - PIQ

PIQ Ann: New Oesophageal Cancer Diagnostic shows strong performance

PIQ Ann: Annual Report to shareholders

PIQ Ann: Preliminary Final Report

PIQ Ann: Corporate Governance Statement and Appendix 4G

PIQ Ann: OxiDx launched to maximise oxidative stress technology

PIQ Ann: Change in substantial holding - Lipscombe

PIQ Ann: Completion of Placement and Exercise of Performance Rights

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Proposed issue of securities - PIQ

PIQ Ann: Proteomics raises $8m in highly successful Placement

PIQ Ann: Trading Halt

PIQ Ann: Reinstatement to Quotation

PIQ Ann: Proteomics signs binding LOI with Sonic Healthcare USA

PIQ Ann: Suspension from Quotation

PIQ Ann: Trading Halt

PIQ Ann: Clinical Utility Study demonstrates PromarkerD test benefits

PIQ Ann: Potential breakthrough blood test for endometriosis

PIQ Ann: June 2022 Quarterly Activities Report and Appendix 4C

PIQ Ann: European PromarkerD patents expanded beyond diabetes

PIQ Ann: Investor Presentation

PIQ Ann: Exercise of Performance Rights

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Endometriosis clinical validation study readout positive

PIQ Ann: Proteomics secures licence to oesophageal cancer biomarkers

PIQ Ann: PromarkerD manufacturing tech-transfer completed

PIQ Ann: Study shows PromarkerD also predicts late-stage renal issues

PIQ Ann: PromarkerD registration submitted to the TGA

PIQ Ann: Investor Presentation - Jefferies MedTech & Biotech summit

PIQ Ann: Proteomics awarded $400,000 funding to support manufacturing

PIQ Ann: March 2022 Quarterly Activities Report and Appendix 4C

PIQ Ann: New Clinical Advisory Board for PromarkerD global rollout

PIQ Ann: Investor Presentation

PIQ Ann: PromarkerD patent granted in India

PIQ Ann: Investor Presentation

PIQ Ann: Appendix 4D and Interim Financial Report

PIQ Ann: PromarkerD completes 'pre-assessment' for Medicare rebate

PIQ Ann: Exercise of Options

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Proteomics identifies novel biomarkers for Asthma and COPD

PIQ Ann: Unique panel of biomarkers identified for oesophageal cancer

PIQ Ann: December 2021 Quarterly Activities Report and Appendix 4C

Register to track PIQ and receive email alerts.

Similar Companies

ADO
BPH
CTE
GSS
GTG
MEM
OSL
PAL